Detail page

Knowledge Web

Person

Ignace B. Vergote

Gynäkologe

Name	Ignace B. Vergote
Place	Löwen (Wirkungsort) Belgien
Academic degree	MD, PhD
Profession	Gynäkologe (characteristic profession) Onkologe Hochschullehrer
Variant	I. Vergote Ignace Vergote I. B. Vergote
Related	Katholieke Universiteit Leuven
Record type	Person
GND-Identifier	173237657
Record ID	173237657
Involved in show all Single-cell profiling in ovarian germ cell and sex cord-stromal tumours Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium Biomarker-based models for preoperative assessment of adnexal mass: A multicenter validation study Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium Is there a role for HIPEC in ovarian cancer? Antiangiogenic therapies in ovarian cancer rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer Shared genetics underlying epidemiological association between endometriosis and ovarian cancer The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO) Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor Chemotherapy for cervical cancer Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Ignace B. Vergote

Single-cell profiling in ovarian germ cell and sex cord-stromal tumours

Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

Biomarker-based models for preoperative assessment of adnexal mass: A multicenter validation study

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium

High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review

Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Is there a role for HIPEC in ovarian cancer?

Antiangiogenic therapies in ovarian cancer

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer

Shared genetics underlying epidemiological association between endometriosis and ovarian cancer

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk

Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report

Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation

Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor

Chemotherapy for cervical cancer

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related